Mercachem logo voor websites

Update COVID-19:

The COVID-19 situation is currently impacting most of the globe, including Asia, Europe and North America. At all MercachemSyncom sites, we follow the recommendations of the local competent authorities as they are released. We have established a series of contingency measures aimed at reducing risks for our employees, their families and the MercachemSyncom Operations. These measures are proactively being reassessed at regular intervals and adapted as deemed appropriate.

The MercachemSyncom team is united and determined to face the situation with the energy, strength and passion that constitute one of our hallmarks.



The European Lead Factory (ELF) works on establishing a compound collection of 500,000 compounds based on non-mainstream scaffolds. Academic research groups and small- and medium-sized enterprises (SMEs) within Europe will have access to the compound library.

A number of companies belonging to the European Federation of Pharmaceutical Industries and Associations (EFPIA) will form a library of 300,000 compounds.

Mercachem is responsible for producing 40,000 compounds from 2012 to 2017 as part of WP12. In this context, we have a good track record and play a major role. We develop complex 3D scaffolds in collaboration with our academic partners: Leiden University, Radboud University Nijmegen, and the Netherlands Cancer Institute in Amsterdam. 

Contact our ELF Team!